now, however, those barriers are being broken down with these new measures, allowing families in all provinces and all areas to have closer access to the proper screenings required to keep infants from progressing further into sma without parents or healthcare providers even being aware of its existence.
taylor diakew, a mother of a young child with sma, said in a press release, “i could not imagine what our life would look like if my daughter were not given genetic sma testing at birth. today, thanks to her early diagnosis and quick access to treatment, she is a happy, healthy little girl who does not exhibit any signs of sma. she is walking, running, climbing, and talking like any other child. thanks to sma newborn screening, she can live the best life possible.”
these new screening measures will help prevent the worst outcome in those living with sma, and couldn’t have been possible without the collaboration of provincial and territorial governments with muscular dystrophy canada and novartis pharmaceuticals canada.
the new initiative also paves the way for better screening for other rare and neuromuscular diseases.
“there are many progressive neuromuscular disorders where time is of the essence: early diagnosis and prompt access to treatments are critical drivers to achieving the best possible outcomes,” said dr. homira osman, vp of research and public policy, muscular dystrophy canada, in a press release. muscular dystrophy canada will now leverage the knowledge and findings gained from this initiative to ensure other neuromuscular disorders are included in newborn screening programs nationwide.”